Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system
C Gastaldon, E Raschi, JM Kane, C Barbui… - Psychotherapy and …, 2020 - karger.com
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
C Gastaldon, E Raschi, JM Kane, C Barbui… - Psychotherapy and …, 2020 - karger.com
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system
C Gastaldon, E Raschi, JM Kane, C Barbui… - PSYCHOTHERAPY …, 2021 - iris.univr.it
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
C Gastaldon, E Raschi, JM Kane… - Psychotherapy and …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective Using the FDA Adverse Event Reporting System (FAERS) database …
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
C Gastaldon, E Raschi, JM Kane… - Psychotherapy & …, 2021 - search.ebscohost.com
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
C Gastaldon, E Raschi, JM Kane, C Barbui… - PSYCHOTHERAPY …, 2021 - cris.unibo.it
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
C Gastaldon, E Raschi, JM Kane, C Barbui… - Psychotherapy and …, 2020 - go.gale.com
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
C Gastaldon, E Raschi, JM Kane, C Barbui… - Psychotherapy and …, 2020 - europepmc.org
Objective Using the FDA Adverse Event Reporting System (FAERS) database (March 2019-
March 2020), we analysed esketamine-related adverse events (AEs) to detect and …
March 2020), we analysed esketamine-related adverse events (AEs) to detect and …
Post-marketing safety concerns with esketamine: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
C Gastaldon, E Raschi, JM Kane, C Barbui… - Psychotherapy and …, 2021 - psycnet.apa.org
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …